Peptide Comparison
SetmelanotidevsTirzepatide
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
At a Glance
Quick
comparison
Dose Range
Setmelanotide
0.5 mg–3 mg mg
Tirzepatide
2.5–15 mg
Frequency
Setmelanotide
Once daily
Tirzepatide
Once weekly
Administration
Setmelanotide
subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle Length
Setmelanotide
Ongoing/indefinite
Tirzepatide
Ongoing/indefinite
Onset Speed
Setmelanotide
Moderate (1-2 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence Level
Setmelanotide
Strong human trials (Phase 3 or FDA approved)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Weight Management
Metabolic Health
Quality of Life
Weight Loss
Appetite Control
Blood Sugar Control
Technical Data
Compound
specifications
Setmelanotide
Molecular Formula
C49H68N18O9S2
Molecular Weight
1,117.3 Da
Half-Life
~11 hours
Bioavailability
~79% subcutaneous bioavailability
CAS Number
920014-72-8
Tirzepatide
Molecular Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Half-Life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS Number
2023788-19-2
Protocols
Dosing
tiers
Setmelanotide
Tirzepatide
Applications
Best
suited for
Setmelanotide
Treating obesity caused by confirmed POMC deficiency mutations
Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing obesity from PCSK1 or LEPR genetic defects
Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hyperphagia and body weight in Bardet-Biedl syndrome
Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing early-onset severe obesity with identified melanocortin pathway mutations
Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.
Safety Profile
Side
effects
Setmelanotide
Common
- Skin Hyperpigmentation
- Injection Site Reactions
- Nausea
- Diarrhea
Uncommon
- Hair Color Darkening and Nevus Changes
Serious
- Depression and Suicidal Ideation
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research Status
Safety
& evidence
Setmelanotide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients.
Contraindications
- xKnown hypersensitivity to setmelanotide or any excipients
- xObesity not caused by POMC, PCSK1, LEPR deficiency or Bardet-Biedl syndrome
- xPatients without genetic confirmation of melanocortin pathway mutations
- xUse during pregnancy (animal studies suggest potential fetal harm)
Tirzepatide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
- xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
- xCurrent or recent pancreatitis
- xPregnancy or planning to become pregnant
Decision Guide
Which is
right for you?
Choose Setmelanotide if...
- Treating obesity caused by confirmed POMC deficiency mutations
- Managing obesity from PCSK1 or LEPR genetic defects
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Addressing early-onset severe obesity with identified melanocortin pathway mutations
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement